Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

ATZ-ADAs were detected in 34% of patients with unresectable HCC and were associated with inferior PFS. ATZ-ADAs may serve as a promising biomarker for predicting treatment response and optimizing therapeutic strategies in HCC.